Donna Sweet, MD
Internal Medicine · Wichita, KSNPI 1982679478
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Viiv Healthcare Company at 42.7% of the total. Reporting peaked in 2019 at $130,428 and has fallen 93.6% since, to $8,380 in 2025. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 309 payments — averaging $599.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$79K
- Gilead$70K
- Janssen Products, LP$17K
- Merck$15K
- Theratechnologies Inc.$2K
- GSK$1K
- plus $428 from 16 others
Across 72 payments — averaging $2260.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$128K
- Merck$34K
What the payments were for
- Consulting fees$47,35026%
- Speaking & faculty fees$102,11555%
- Travel & lodging$26,28814%
- Food & beverage$9,3595%
- Education$1770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 106 | $79,102 |
| Gilead | 114 | $70,375 |
| Janssen Products, LP | 25 | $16,857 |
| Merck | 26 | $15,461 |
| Theratechnologies Inc. | 2 | $2,000 |
| GSK | 10 | $1,066 |
| Johnson & Johnson(2 entities) | 9 | $110 |
| Pfizer | 2 | $41 |
| Dexcom, Inc. | 1 | $30 |
| AbbVie | 2 | $28 |
| Janssen Scientific Affairs, LLC | 1 | $27 |
| Abbott | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
| Napo Pharmaceuticals Inc | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
| Bayer | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$185,290 in reported general payments places this provider in the 95th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 5,498 | $1,687,938 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 6,992 | $1,487,597 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 260 | $1,030,591 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 1,372 | $417,838 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 84 | $344,249 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 51 | $244,848 |
| PrezcobixDarunavir/Cobicistat | 69 | $165,869 |
| DescovyEmtricitabine/Tenofov Alafenam | 61 | $135,603 |
| TivicayDolutegravir Sodium | 35 | $134,447 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 1,765 | $115,629 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 29 | $113,482 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 11 | $105,562 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 24 | $98,620 |
| DovatoDolutegravir Sodium/Lamivudine | 32 | $92,652 |
| EliquisApixaban | 101 | $79,426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKShingrix, Arexvy, Twinrix, Trelegy Ellipta | $1,066 | $1,940,6728,514 claims |
| PfizerAbrysvo, Eliquis | $41 | $1,767,3645,599 claims |
| GileadBiktarvy, Genvoya, Descovy, Stribild, Vemlidy | $70,375 | $1,627,675442 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Juluca, Triumeq | $79,102 | $349,396101 claims |
| Janssen Products, LPSymtuza | $16,857 | $244,84851 claims |
| Johnson & JohnsonPrezcobix, Complera, Xarelto, Invega Sustenna | $110 | $229,147107 claims |
| MerckIsentress, Januvia, Isentress Hd, Pifeltro | $15,461 | $195,497144 claims |
| Lilly USA, LLCTrulicity | $14 | $22,58927 claims |
| Janssen Scientific Affairs, LLCPrezista | $27 | $17,49912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Wichita
- Wissam SalibaWichita$155K
- Atieh JibbeWichita$121K
- Thanh TruongWichita$28K
- Maya EstephanWichita$12K
- Baoluan NguyenWichita$7K
- Jane GitauWichita$5K
- Felix TarmWichita$5K
- Hannah LaiWichita$5K
- Ronnie MoussaWichita$4K
- Shadi HamdehKansas City$959K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.